China CDC weekly · 2025
Antibody Levels Against Mumps Virus in Children After Implementation of the Two-Dose MMR Vaccine Policy - Fujian Province, China, 2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Zhifei, Chen Rui, Wu Ruihong, Zhang Suhan, Yang Xiuhui, Pan Weiyi, Zhang Hairong, Zhang Mengping, Zhou Yong, Li Dong
Аннотация
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The Measles-Mumps-Rubella (MMR) vaccine plays a crucial role in preventing mumps. Before the implementation of the two-dose MMR vaccine policy, baseline data on mumps virus antibody seroprevalence and geometric mean concentrations (GMCs) among children and adolescents in Fujian Province were available.
WHAT IS ADDED BY THIS REPORT?: This report provides a post-policy evaluation following the introduction of Fujian's two-dose MMR policy in June 2020. The 2023 survey shows an overall seroprevalence of 79.53% and a GMC of 265.61 U/mL. Compared with 2018, significant improvements were observed in children under 2 years; however, a concerning decline was noted among adolescents aged 15-17 years. Antibody levels peaked shortly after vaccination, and two doses were found to confer significantly higher immunity than one dose within a 270-day period.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES?: The two-dose MMR policy has been effective in improving early childhood immunity. However, the observed waning immunity in adolescents underscores the urgent need for ongoing serological surveillance, particularly in individuals aged 6-19 years, to inform potential recommendations for booster vaccinations.
WHAT IS ADDED BY THIS REPORT?: This report provides a post-policy evaluation following the introduction of Fujian's two-dose MMR policy in June 2020. The 2023 survey shows an overall seroprevalence of 79.53% and a GMC of 265.61 U/mL. Compared with 2018, significant improvements were observed in children under 2 years; however, a concerning decline was noted among adolescents aged 15-17 years. Antibody levels peaked shortly after vaccination, and two doses were found to confer significantly higher immunity than one dose within a 270-day period.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES?: The two-dose MMR policy has been effective in improving early childhood immunity. However, the observed waning immunity in adolescents underscores the urgent need for ongoing serological surveillance, particularly in individuals aged 6-19 years, to inform potential recommendations for booster vaccinations.